AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05105724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
Study NCT02990806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-071
Description: IV infusion.
Study NCT02990806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remicade
Description: IV infusion.
Study NCT02457819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
Study NCT01914172 — intervention group
Intervention type: OTHER
Intervention: online questionairres
Description: see group descriptions
Study NCT03112148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg dose MR formulations,10 mg dose of tofacitinib IR solution
Description: For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state.
Study NCT03088878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
Description: Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
Study NCT03088878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (300mg) plus Ibrutinib
Description: Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
Study NCT03088878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (600 mg) plus ibrutinib
Description: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
Study NCT03088878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab (RDR) plus ibrutinib
Description: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
Study NCT03088878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab plus ibrutinib
Description: Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
Study NCT02460484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Cord Blood Infusion
Description: Intravenous infusion
Study NCT01949740 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01949740 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03088878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib alone
Description: Arm B: Participants will receive ibrutinib (420 mg) orally once daily
Study NCT01242462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mid-frequency Ventilation
Description: Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is >/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH >/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
Study NCT04528732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (G-CBT)
Description: G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
Study NCT04528732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Group (MFG)
Description: MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
Study NCT02674451 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
Study NCT02674451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
Study NCT01099891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhEGF
Description: rhEGF 50 μg/ml, spray type, twice a day
Study NCT01099891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Spray type, Twice a day
Study NCT01215019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 20% Mannitol, 1-5 doses as needed to control ICP
Study NCT01215019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: 3% sodium chloride injection, 1-5 doses, as needed to control ICP
Study NCT02476890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 100 mg
Description: Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
Study NCT02476890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
Study NCT02135172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting
Study NCT02135172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Study NCT02135172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Study NCT02572024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: Baroreflex activation therapy device ON
Study NCT02572024 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baroreflex activation therapy device OFF
Study NCT02606409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
Study NCT02606409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol sedation at a starting dose of 10-70 µg/kg/hour.
Study NCT01301469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.42 in plasma adapted Ringer's solution
Description: 60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
Study NCT01301469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% HES 130/0.4 in a saline solution
Description: 60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
Study NCT05561036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome doxorubicin
Description: Liposome doxorubicin (50mg/m2) or intravenous placebo with a treatment cycle of once every 28 days
Study NCT05561036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline solution
Study NCT02275325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative vestibular rehabilitation
Description: 12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
Study NCT02914522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02914522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02914522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02537522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 8.5 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
Study NCT02537522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses with 9.0 BC
Description: Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
Study NCT02533713 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exoskeleton assisted gait training
Description: Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
Study NCT02533713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton assisted gait training
Description: Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
Study NCT01521624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
Study NCT03312439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Given advice
Description: Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
Study NCT02680093 — intervention group
Intervention type: OTHER
Intervention: Cervical length in pregnant women.
Description: Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes.
Study NCT00300040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemoglobin glutamer 250 - bovine
Description: intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
Study NCT00300040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Hydroxyethylstarch
Description: 250ml for intravenous infusion
Study NCT04329663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indonesian computer-based game prototype
Description: In order to improve the ADHD clinical symptoms and executive function of the player, this game should has challenge similar to memory game which is the player was given object to be memorized and then match the object in accordance to the task given inside the game. With some difficulty leves, this game was tried to trigger players in terms of accuracy and quickness in completing the mission.
Study NCT03692520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
Study NCT04352452 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: differences in musculoskeletal and cognitive stress
Study NCT02729272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic colpotomy by ultrasonic ESD
Description: In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
Study NCT02729272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colpotomy by monopolar ESD
Description: In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
Study NCT02729272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar ESD
Study NCT02729272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ESD
Study NCT03649165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
Study NCT03649165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
Study NCT02013466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS A
Description: High-whey protein, leucine-rich, low-caloric ONS in powder format
Study NCT02013466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS B
Description: High casein-protein, low-caloric control product (isocaloric to product A)
Study NCT02013466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS C
Description: High casein-protein, high-caloric control product.
Study NCT02013466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bolus ONS D
Description: high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
Study NCT00541892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium with no human serum albumine added
Description: See above
Study NCT00541892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medium
Description: See above
Study NCT00184106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
Description: Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
Study NCT00184106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
Description: Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
Study NCT02639793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
Study NCT02833649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Implantable collamer Lens
Description: The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
Study NCT00000271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
Study NCT00000271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
Study NCT03647371 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Macintosh laryngoscopy
Description: intubation with MAcintosh laryngoscopy after anesthetic induction
Study NCT03647371 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: McGrath MAC video laryngoscopy
Description: intubation with McGrath MAC videolaryngoscopy after anesthetic induction
Study NCT04686994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC 41
Description: Oral tablets
Study NCT04686994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASC 41 Placebo
Description: Oral tablets
Study NCT02800512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic sacrocolpopexy
Description: Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
Study NCT02800512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high uterosacral ligament suspension
Description: Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
Study NCT04813172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Assessment
Description: Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit.
Study NCT00375882 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hypothermia
Study NCT00375882 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cochlear implantation with mild hypothermia
Study NCT03885739 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Pericapsular Nerve Group block
Description: Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
Study NCT04236206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Short Message Service
Description: SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~* The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~* The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~* Patients will be encouraged to send messages/call the researcher for any queries encountered.
Study NCT00584220 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A toric
Description: contact lens
Study NCT00584220 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: alphafilcon A toric
Description: contact lens
Study NCT04207957 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Olorofim
Description: 150 mg